News articles about Tocagen (NASDAQ:TOCA) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Tocagen earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.6826933298617 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of TOCA stock opened at $9.06 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.56 and a current ratio of 4.56. Tocagen has a 1 year low of $8.31 and a 1 year high of $14.66.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.25). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $2.01 million. Tocagen had a negative return on equity of 70.79% and a negative net margin of 130,944.75%. equities analysts anticipate that Tocagen will post -2.07 earnings per share for the current year.
Several equities research analysts recently commented on the stock. ValuEngine raised shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Monday, July 2nd. LADENBURG THALM/SH SH began coverage on shares of Tocagen in a research report on Wednesday, June 27th. They issued a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research upgraded shares of Tocagen from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Wednesday, May 16th. B. Riley began coverage on shares of Tocagen in a research note on Wednesday, May 16th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, HC Wainwright began coverage on shares of Tocagen in a research note on Monday, June 11th. They issued a “buy” rating and a $14.50 price target on the stock. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $15.13.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Featured Story: What does RSI mean?
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.